The practice of routinely maintaining PIVC access has not only benefits but also risks. It’s due for a mindset shift, with ...
Shares of CorMedix Inc. (CRMD) soared 8% in the pre-market session on Wednesday after the company raised its full-year ...
In view of the alarming rise of cancer cases across the country and to make advanced, integrated oncology care accessible in ...
Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study – Cash burn of $4.2 million in Q3 remains in line with ...
Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...
VVT Med Inc. ("VVT Med" or the "Company"), a leader in next-generation, minimally invasive, non-thermal, and non-tumescent ("NT-NT") solutions for venous disease, is pleased to announce several ...
For more than two decades, Bracco has made education a cornerstone of progress in radiology. In 2024 alone, Bracco's educational programs reached over 100,000 healthcare professionals worldwide, ...
To address the growing burden of cancer and make advanced oncology care more accessible in southern India, SPARSH Group of ...
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr ...
Gore & Associates announced trial results evaluating the investigational Viabahn Fortegra venous stent for the treatment of ...
InterVene, Inc. recently announced that it has received 510(k) clearance from the FDA for its Recana thrombectomy catheter ...
Medical Device Network on MSN
Gore’s venous stent study meets primary endpoint
The trial assessed the performance of the device over 12 months in individuals experiencing symptomatic deep venous disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback